The global blood glucose monitoring devices market size was estimated at USD 15.53 billion in 2025 and is projected to reach USD 30.18 billion by 2033, growing at a CAGR of 8.8% from 2026 to 2033. The market is primarily influenced by the growing prevalence of diabetes and growing elderly population susceptible to conditions such as diabetes.
In addition, market growth is driven by rising awareness of preventive measures for diabetes and the introduction of new products. Diabetes, a widespread and increasing global concern, is characterized by the pancreas' inability to efficiently produce insulin, leading to elevated blood glucose levels. Moreover, the technology associated with blood glucose monitoring not only aids immediate intervention but also serves as a valuable tool for patient education on diabetes and its effective management.
The rising global prevalence of diabetes is anticipated to drive strong market demand during the forecast period. According to the Institute for Health Metrics and Evaluation (June 2023), over 500 million people worldwide currently live with diabetes, impacting individuals across all demographics. With a global prevalence of 6.1%, diabetes ranks among the top 10 causes of death and disability. North Africa and the Middle East lead with a 9.3% prevalence, which is expected to increase to 16.8% by 2050. In Latin America and the Caribbean, the prevalence is projected to rise to 11.3%.
In addition, market growth is driven by rising awareness of preventive measures for diabetes and the introduction of new products. Diabetes, a widespread and growing global concern, is characterized by the pancreas' inability to efficiently produce insulin, leading to elevated blood glucose levels. According to the International Diabetes Federation, approximately 537 million individuals were diagnosed with diabetes in 2021, and projections indicate an anticipated rise to 643 million by 2030 and 783 million by 2045.
Blood glucose monitoring (BGM) devices play a crucial role in supporting individuals with diabetes in numerous ways. Initially, they empower both patients and healthcare professionals to identify elevated or reduced blood glucose levels, enabling timely adjustments to treatment plans. This capability serves as a protective measure by promptly confirming acute hypoglycemia or hyperglycemia, ensuring the well-being of patients. In addition, these devices enhance self-care practices, offering individuals greater control over their diabetes management. Moreover, the technology associated with blood glucose monitoring not only aids in immediate intervention but also serves as a valuable tool for patient education on diabetes and its effective management.
The prevalence of diabetes tends to increase with age, and older adults are more susceptible to developing diabetes or experiencing complications related to the disease. As the geriatric population increases, so does the pool of individuals at risk of diabetes, creating a greater demand for blood glucose monitoring devices. For instance, based on the National Diabetes Statistics Report, in 2021, in the U.S. 27.2 million adults aged 65 years or older had prediabetes. Studies have shown that real-time continuous glucose monitoring (CGM) is effective and safe in adults aged 65 years and older with type 2 diabetes. Participants aged 65 years and above showed a significant improvement in their hemoglobin A1c (HbA1c) levels, which indicates better control of blood glucose levels when using CGM compared to blood glucose monitoring (BGM). These results underscore the potential value of CGM devices as a beneficial tool for effectively managing diabetes in the elderly population.
The COVID-19 pandemic has significantly impacted the market. The pandemic highlighted healthcare disparities and technological importance, including BGM devices. Regulatory changes, such as relaxed requirements for obtaining continuous glucose monitoring (CGM), have increased access to these devices, particularly benefiting those who can benefit from the technology. Furthermore, the use of real-time continuous glucose monitoring (rtCGM) was observed during lockdowns for improved glycemic control, reducing the time in range & glucose variability, thereby significantly boosting the overall market growth.
In addition, market growth is driven by rising awareness of preventive measures for diabetes and the introduction of new products. Diabetes, a widespread and increasing global concern, is characterized by the pancreas' inability to efficiently produce insulin, leading to elevated blood glucose levels. Moreover, the technology associated with blood glucose monitoring not only aids immediate intervention but also serves as a valuable tool for patient education on diabetes and its effective management.
The rising global prevalence of diabetes is anticipated to drive strong market demand during the forecast period. According to the Institute for Health Metrics and Evaluation (June 2023), over 500 million people worldwide currently live with diabetes, impacting individuals across all demographics. With a global prevalence of 6.1%, diabetes ranks among the top 10 causes of death and disability. North Africa and the Middle East lead with a 9.3% prevalence, which is expected to increase to 16.8% by 2050. In Latin America and the Caribbean, the prevalence is projected to rise to 11.3%.
In addition, market growth is driven by rising awareness of preventive measures for diabetes and the introduction of new products. Diabetes, a widespread and growing global concern, is characterized by the pancreas' inability to efficiently produce insulin, leading to elevated blood glucose levels. According to the International Diabetes Federation, approximately 537 million individuals were diagnosed with diabetes in 2021, and projections indicate an anticipated rise to 643 million by 2030 and 783 million by 2045.
Blood glucose monitoring (BGM) devices play a crucial role in supporting individuals with diabetes in numerous ways. Initially, they empower both patients and healthcare professionals to identify elevated or reduced blood glucose levels, enabling timely adjustments to treatment plans. This capability serves as a protective measure by promptly confirming acute hypoglycemia or hyperglycemia, ensuring the well-being of patients. In addition, these devices enhance self-care practices, offering individuals greater control over their diabetes management. Moreover, the technology associated with blood glucose monitoring not only aids in immediate intervention but also serves as a valuable tool for patient education on diabetes and its effective management.
The prevalence of diabetes tends to increase with age, and older adults are more susceptible to developing diabetes or experiencing complications related to the disease. As the geriatric population increases, so does the pool of individuals at risk of diabetes, creating a greater demand for blood glucose monitoring devices. For instance, based on the National Diabetes Statistics Report, in 2021, in the U.S. 27.2 million adults aged 65 years or older had prediabetes. Studies have shown that real-time continuous glucose monitoring (CGM) is effective and safe in adults aged 65 years and older with type 2 diabetes. Participants aged 65 years and above showed a significant improvement in their hemoglobin A1c (HbA1c) levels, which indicates better control of blood glucose levels when using CGM compared to blood glucose monitoring (BGM). These results underscore the potential value of CGM devices as a beneficial tool for effectively managing diabetes in the elderly population.
The COVID-19 pandemic has significantly impacted the market. The pandemic highlighted healthcare disparities and technological importance, including BGM devices. Regulatory changes, such as relaxed requirements for obtaining continuous glucose monitoring (CGM), have increased access to these devices, particularly benefiting those who can benefit from the technology. Furthermore, the use of real-time continuous glucose monitoring (rtCGM) was observed during lockdowns for improved glycemic control, reducing the time in range & glucose variability, thereby significantly boosting the overall market growth.
Global Blood Glucose Monitoring Devices Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global blood glucose monitoring devices market report on the basis of product, connectivity, end use, and region:Product Outlook (Revenue, USD Million, 2021-2033)
- Self-Monitoring Devices
- Continuous Glucose Monitoring (CGM) Devices
Connectivity Outlook (Revenue, USD Million, 2021-2033)
- Bluetooth-Enabled Devices
- Wi-Fi-Enabled Devices
- Near Field Communication (NFC) Devices
- USB Connectivity Devices
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Home Care
- Diagnostic Centers
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Blood Glucose Monitoring Devices Market: Executive Summary
Chapter 3. Blood Glucose Monitoring Devices Market Variables, Trends, & Scope
Chapter 4. Blood Glucose Monitoring Devices: Product Estimates & Trend Analysis
Chapter 5. Blood Glucose Monitoring Devices: Connectivity Estimates & Trend Analysis
Chapter 6. Blood Glucose Monitoring Devices: End Use Estimates & Trend Analysis
Chapter 7. Regional Business Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this Blood Glucose Monitoring Devices market report include:- Abbott Laboratories
- Senseonics Holdings, Inc.
- GlucoRx Limited
- Zhejiang POCTech Co., Ltd
- i-SENS, Inc.
- Nemaura Medical Inc.
- Sinocare, Inc.
- Bionime
- AgaMatrix
- Medtronic plc
- F. Hoffmann-La Roche Ltd
- Dexcom, Inc.
- Sanofi
- Novo Nordisk
- Insulet Corporation
- Ypsomed Holdings
- Glysens Incorporated
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | January 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 15.53 Billion |
| Forecasted Market Value ( USD | $ 30.18 Billion |
| Compound Annual Growth Rate | 8.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 18 |
